Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

We expect Amgen AMGN to beat expectations when it reports fourth-quarter and full-year 2024 results on Feb. 4, after market ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...